73/100BRegeneron Pharmaceuticals stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Regeneron Pharmaceuticals is 887.79, 1.8% below the current price of 904.38. Their targets range from 756.00 to 1,100.00.
Of the 25 firms that rated Regeneron Pharmaceuticals in the past 12 months, 17 rate it buy or strong buy, 8 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 756.00 to 1,100.00, with an average of 887.79.
| Buy | 17 | |
| Hold | 8 | |
| Sell | 0 |
12-month price target
| Highest target | 1,100.00 |
| Average target | 887.79 |
| Lowest target | 756.00 |
| Current price | 904.38 |
Regeneron Pharmaceuticals price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Regeneron Pharmaceuticals price target and rating?
How analysts rate Regeneron Pharmaceuticals, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
17 of 25 firms rate it buy now, against 13 of 20 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Regeneron Pharmaceuticals analyst upgrades, downgrades and price targets
The latest rating change came on 15 October 2026, when UBS upgraded Regeneron Pharmaceuticals from Neutral to Buy. The most recent new target came from Cantor Fitzgerald on 2 November 2026: 980.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 2 Nov 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Overweight | 795.00 → 980.00 | +23.3% | 962.36 |
| 2 Nov 2026 | Wells Fargo | Reiterated · Equal Weight | 925.00 → 1,030.00 | +11.4% | 927.89 |
| 2 Nov 2026 | Guggenheim Yatin Suneja | Reiterated · Buy | 1,030.00 → 1,100.00 | +6.8% | 927.89 |
| 2 Nov 2026 | Wells Fargo Mohit Bansal | — | 750.00 → 925.00 | +23.3% | 927.89 |
| 30 Oct 2026 | Robert W. Baird Brian Skorney | — | 761.00 → 875.00 | +15.0% | 927.89 |
| 19 Oct 2026 | Piper Sandler | Reiterated · Overweight | 854.00 → 865.00 | +1.3% | 790.74 |
| 15 Oct 2026 | UBS | Upgraded · Neutral → Buy | — | — | — |
| 14 Oct 2026 | UBS | — | 978.00 | — | 778.36 |
| 8 Oct 2026 | RBC Capital Brian Abrahams | Reiterated · Sector Perform | 737.00 → 810.00 | +9.9% | 730.08 |
| 8 Oct 2026 | Raymond James Chris Raymond | — | 910.00 → 911.00 | +0.1% | 742.12 |
| 7 Oct 2026 | Truist Financial | Reiterated · Buy | 769.00 → 780.00 | +1.4% | 747.51 |
| 7 Oct 2026 | Morgan Stanley | Reiterated · Equal Weight | 758.00 → 779.00 | +2.8% | 743.60 |
| 1 Oct 2026 | Jefferies | Reiterated · Buy | 930.00 | — | 741.16 |
| 1 Oct 2026 | BMO Capital Evan David Seigerman | — | 730.00 → 920.00 | +26.0% | 741.41 |
| 1 Oct 2026 | Argus Research | Upgraded · Hold → Buy | 850.00 | — | 758.27 |
| 10 Sept 2026 | HSBC Rajesh Kumar | Reiterated · Buy | 800.00 → 920.00 | +15.0% | 807.65 |
| 17 Aug 2026 | Leerink Partners David Risinger | Reiterated · Market Perform | 641.00 → 824.00 | +28.5% | 803.48 |
| 14 Aug 2026 | Bernstein Jeffrey Walch | — | 921.00 → 756.00 | -17.9% | 799.46 |
| 3 Aug 2026 | Guggenheim | Reiterated · Buy | 1,000.00 → 1,030.00 | +3.0% | 763.51 |
| 31 Jul 2026 | RBC Capital | Reiterated · Sector Perform | 707.00 → 737.00 | +4.2% | 739.50 |
| 31 Jul 2026 | Morgan Stanley | Reiterated · Equal Weight | 730.00 → 758.00 | +3.8% | 738.82 |
| 31 Jul 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Overweight | 750.00 → 795.00 | +6.0% | 742.59 |
| 31 Jul 2026 | Robert W. Baird | — | 742.00 → 761.00 | +2.6% | 738.34 |
| 31 Jul 2026 | Wells Fargo | Reiterated · Equal Weight | 700.00 → 750.00 | +7.1% | 738.34 |
| 21 Jul 2026 | Guggenheim Yatin Suneja | Reiterated · Buy | 995.00 → 1,000.00 | +0.5% | 675.72 |
| 9 Jul 2026 | Piper Sandler Biren Amin | Reiterated · Overweight | 855.00 → 854.00 | -0.1% | 662.88 |
| 8 Jul 2026 | Morgan Stanley Terence Flynn | Reiterated · Equal Weight | 788.00 → 730.00 | -7.4% | 676.23 |
| 7 Jul 2026 | Truist Financial | Reiterated · Buy | 778.00 → 769.00 | -1.2% | 670.54 |
| 7 Jul 2026 | Benchmark | Upgraded · Hold → Buy | — | — | — |
| 6 Jul 2026 | HSBC | Reiterated · Buy | 985.00 → 800.00 | -18.8% | 643.00 |
| 6 Jul 2026 | Cantor Fitzgerald | Reiterated · Overweight | 800.00 → 750.00 | -6.3% | 654.27 |
| 19 May 2026 | Canaccord Genuity John Newman | Reiterated · Buy | 1,057.00 → 875.00 | -17.2% | 629.68 |
| 18 May 2026 | Wolfe Research Alexandria Hammond | — | 860.00 | — | 629.36 |
| 18 May 2026 | Evercore ISI | — | 875.00 → 825.00 | -5.7% | 619.84 |
| 18 May 2026 | RBC Capital | Reiterated · Sector Perform | 765.00 → 707.00 | -7.6% | 619.62 |
| 18 May 2026 | Truist Financial | Reiterated · Buy | 796.00 → 778.00 | -2.3% | 619.95 |
| 18 May 2026 | BMO Capital | Reiterated · Outperform | 850.00 → 730.00 | -14.1% | 698.25 |
| 18 May 2026 | Piper Sandler | Reiterated · Overweight | 855.00 | — | 698.25 |
| 18 May 2026 | Leerink Partners Market Perform | Downgraded · Outperform → Market Perform | 873.00 → 641.00 | -26.6% | 698.25 |
| 18 May 2026 | Citigroup | Downgraded · Buy → Neutral | — | — | — |
| 1 May 2026 | Guggenheim Yatin Suneja | Reiterated · Buy | 975.00 → 995.00 | +2.1% | 707.06 |
| 30 Apr 2026 | Morgan Stanley Terence Flynn | — | 796.00 → 788.00 | -1.0% | 703.18 |
| 30 Apr 2026 | Truist Financial | Reiterated · Buy | 818.00 → 796.00 | -2.7% | 692.75 |
| 30 Apr 2026 | Barclays | Reiterated · Overweight | 923.00 → 917.00 | -0.7% | 686.36 |
| 22 Apr 2026 | Raymond James Chris Raymond | — | 870.00 → 910.00 | +4.6% | 746.58 |
| 10 Apr 2026 | Morgan Stanley | Reiterated · Equal Weight | 769.00 → 796.00 | +3.5% | 746.15 |
| 8 Apr 2026 | Bernstein | Reiterated · Outperform | 916.00 → 921.00 | +0.5% | 775.53 |
| 9 Mar 2026 | Truist Financial Greg Renza | — | 798.00 → 818.00 | +2.5% | 770.32 |
| 6 Mar 2026 | Barclays Eliana Merle | — | 923.00 | — | 764.93 |
| 2 Mar 2026 | RBC Capital Brian Abrahams | Reiterated · Sector Perform | 745.00 → 765.00 | +2.7% | 784.06 |
Regeneron Pharmaceuticals EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Regeneron Pharmaceuticals's EPS to grow 23.4% a year until 2028, faster than over the last 5 years (6.3% a year) and the last 3 years (2.8%).
Analysts expect Regeneron Pharmaceuticals's revenue to grow 14.9% a year until 2028, faster than over the last 5 years (11.0% a year) and the last 3 years (5.6%).
Revenue
EPS
Does Regeneron Pharmaceuticals beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 16.2% off the result, either way, and their revenue estimate 5.6%, over the last 12 quarters.
- EPS beats
- 105 / 129
- Revenue beats
- 60 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +14.5%
- Since
- January 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Oct 2026 | 16.51 | 20.07 | +21.6% | 4.58B | 5.12B | +11.6% |
| Q2 FY2026 | 30 Jul 2026 | 10.16 | 14.29 | +40.6% | 3.82B | 4.29B | +12.4% |
| Q1 FY2026 | 29 Apr 2026 | 8.91 | 9.47 | +6.3% | 3.48B | 3.61B | +3.6% |
| Q4 FY2025 | 30 Jan 2026 | 10.74 | 11.44 | +6.5% | 3.81B | 3.88B | +1.9% |
| Q3 FY2025 | 28 Oct 2025 | 9.65 | 11.83 | +22.6% | 3.59B | 3.75B | +4.5% |
| Q2 FY2025 | 1 Aug 2025 | 8.43 | 12.89 | +52.9% | 3.29B | 3.68B | +11.8% |
| Q1 FY2025 | 29 Apr 2025 | 8.62 | 8.22 | -4.6% | 3.25B | 3.03B | -6.8% |
| Q4 FY2024 | 4 Feb 2025 | 11.21 | 12.07 | +7.7% | 3.74B | 3.79B | +1.3% |
| Q3 FY2024 | 31 Oct 2024 | 11.69 | 12.46 | +6.6% | 3.67B | 3.72B | +1.2% |
| Q2 FY2024 | 1 Aug 2024 | 10.61 | 11.56 | +9.0% | 3.38B | 3.55B | +4.8% |
| Q1 FY2024 | 2 May 2024 | 10.17 | 9.55 | -6.1% | 3.23B | 3.15B | -2.5% |
| Q4 FY2023 | 2 Feb 2024 | 10.73 | 11.86 | +10.5% | 3.29B | 3.43B | +4.2% |
Regeneron Pharmaceuticals stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Regeneron Pharmaceuticals's earnings grow at the 20.6% a year analysts expect to FY2028, then 15.0% a year, it would earn about 103.06 a share in FY2030. At the P/E it has traded at over the last five years (8.3 to 23.7) that is 851.88 to 2,443.06 a share, or 1,792.91 at its average P/E of 17.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 67.55 | 558.38 | 1,175.19 | 1,601.34 |
| FY2027 | 70.32 | 581.29 | 1,223.41 | 1,667.04 |
| FY2028 | 77.93 | 644.14 | 1,355.70 | 1,847.30 |
| FY2029 (extrapolated) | 89.62 | 740.76 | 1,559.05 | 2,124.40 |
| FY2030 (extrapolated) | 103.06 | 851.88 | 1,792.91 | 2,443.06 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (8.3, 17.4, 23.7).
Is Regeneron Pharmaceuticals stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Regeneron Pharmaceuticals's P/E of 19.3 is above the middle of its 5-year range (7.4 to 30.5, median 17.4). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Buyers pay less for each point of growth than usual: a PEG of 0.8 on expected growth against 2.7 on its median P/E and past five years' growth. At its usual P/E (17.4 × EPS of 46.95), Regeneron Pharmaceuticals's fair value is 814.64; the price, 904.38, is 11.0% above it. Its forward P/E, on the consensus for FY2026, is 13.4.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (7.4 and 30.5). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 19.26
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 17.35
- Five-year P/E range
- 7.4 – 30.5
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 13.39
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 0.93
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- -1.8%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 194.93146Price 99.09244 | +96.7% | |
| 42.225 | 82.9546Price 42.23165 | +96.4% | |
| 186.680 | 360.82271Price 186.68451 | +93.3% | |
| 213.670 | 405.57304Price 213.67507 | +89.8% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 160.650 | 300.09225Price 160.65375 | +86.8% | |
| 165.860 | 308.95212Price 165.86442 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.